Compound tablet composed of cefprozil and probenecid and preparation method thereof
Through the dry granulation process and formulation optimization of cefpropylene and probenecidum compound tablets, the problem of poor efficacy of cefpropylene is solved, significantly improves antibacterial efficacy and compliance, extends the half-life and blood drug concentration, and realizes the antibacterial drug Effectively reignite.
Patent Information
- Application Number
- CN202411032358.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
The sensitivity of existing cefpropylene antibacterial drugs to most pathogens is greatly reduced, resulting in poor or ineffective therapeutic effects, and lack of oral solid preparations for cefpropylene and probenecidum, making it difficult to optimize pharmacokinetic-pharmacodynamic properties to improve antibacterial efficacy.
Develop a compound tablet composed of cefpropylene and probenecid. Through dry granulation process and optimized formula, combined with binders, disintegrants and glidants, the half-life and blood concentration of cefpropylene are prolonged and the blood drug concentration are improved, and antibacterial efficacy is improved. .
It significantly prolongs the half-life and blood drug concentration of cefpropylene, improves antibacterial efficacy, improves efficacy and compliance, reduces the induction of drug-resistant strains, and achieves effective rekindling of antibacterial drugs.
Smart Images

Figure CN118903035A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a compound tablet composed of cefprozil and probenecid and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. Background Art
[0002] Cefprozil is a second-generation oral broad-spectrum cephalosporin antibiotic, which is mainly used clinically for mild and moderate infections caused by sensitive bacteria, including respiratory tract, skin and soft tissue infections. Its mechanism of action is to inhibit the synthesis of bacterial cell walls. Cefprozil has the advantages of strong antibacterial effect, penicillinase resistance, good clinical efficacy, low toxicity, and fewer allergic reactions than penicillin. Its structural formula is as follows:
[0003]
[0004] Similar to other cephalosporins, cefprozil contains a β-lactam ring in its molecular structure. The β-lactam ring is the most unstable part of the structure of this type of compound. If the ring is broken, the antibacterial effect disappears. Usually, cefprozil is prone to hydrolysis and ring opening when it encounters acid, alkali or β-lactamase, thus losing its antibacterial activity; and metal ions, high temperature and oxidants can catalyze the above reaction. During the preparation and storage of cefprozil preparations, the β-lactam ring of the raw material must be prevented from opening and degrading to ensure the stability of the preparation.
[0005] Probenecid (PROB) belongs to the sulfonamide class of drugs. It is poorly soluble in water and is often prepared as an oral preparation. It is clinically used to treat gout and hyperuricemia. It mainly inhibits the reabsorption of uric acid by the kidneys and increases the excretion of uric acid, thereby reducing the concentration of uric acid. When used in combination with β-lactam drugs to form a compound preparation, it can effectively prolong the half-life (t1 / 2) of β-lactam antibiotics and increase the area under the drug-time curve (AUC).
[0006] Against the backdrop of the continuous occurrence, development and widespread spread of bacterial resistance, the antibacterial efficacy of almost all antibacterial drugs has continued to decline, with cefprozil being a typical example. The sensitivity of cefprozil to most pathogens in its antibacterial spectrum has been greatly reduced, such as Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis. Therefore, the current use of cefprozil to treat infections caused by these pathogens is basically in a dilemma of poor efficacy or even ineffectiveness.
[0007] Given that the R&D pipeline of new antibacterial drugs (with new mechanisms of action) is almost dry, the number of new antibacterial drugs to be discovered in the future is limited. Against this backdrop, optimizing the pharmacokinetic-pharmacodynamic (PK-PD) properties of existing antibacterial drugs, including cefprozil, and thereby fully rekindling the effectiveness and rational use of these antibacterial drugs is a matter of great clinical value and social significance.
[0008] At present, there are related studies on the combination of β-lactam antibiotics (including penicillins and cephalosporin antibiotics) and probenecid (or salts) both at home and abroad, but the oral solid preparation of cefoperazone and probenecid is still blank. Summary of the invention
[0009] The object of the present invention is to provide a compound tablet composed of cefprozil and probenecid and a preparation method thereof, which fills the gap of cefprozil and probenecid compound preparations at home and abroad, and solves the major defect that the existing single cefprozil has extremely poor efficacy or is completely ineffective. Cefprozil and probenecid tablets are improved new compound solid preparations (tablets) composed of two approved drugs, cefprozil and probenecid, according to a certain prescription ratio, which improves various pharmacokinetic-pharmacodynamic (PK-PD) properties of cefprozil. Probenecid competitively inhibits the excretion of cefprozil in the kidney, thereby significantly prolonging the half-life of cefprozil, multiplying the area under the drug-time curve, and significantly prolonging the time when the blood drug concentration of cefprozil exceeds the MICs of the corresponding pathogens as shown in Table 1, thereby fundamentally optimizing the PK-PD parameter T>MIC that is most relevant to the antibacterial efficacy of cefprozil.
[0010] Rhesus monkey PK test study showed:
[0011]
[0012] Table 1: Comparison of 6h / 12h blood drug concentrations of compound cefaclor tablets and single cefaclor tablets
[0013] Compared with the single-ingredient preparation of cefprozil, the most prominent comparative advantage of the compound preparation of cefprozil probenecid tablets is that the single-ingredient preparation is on the verge of failure, while the compound preparation is effective and efficient; the compound preparation not only has reliable efficacy, but also has actually improved compliance. Effective treatment is reasonable treatment, which not only relieves the patient's pain and promotes the patient's early recovery, but also reduces the further induction of drug-resistant strains. It is an important part of the evaluation criteria for the rational use of antimicrobial drugs.
[0014] The technical solution of the present invention is achieved in this way: a compound tablet composed of cefprozil and probenecid, characterized in that cefprozil and probenecid are active ingredients.
[0015] The cefprozil is a monohydrate compound (such as Figure 1 shown).
[0016] The tablet comprises a tablet core and a film coating layer. The tablet core comprises, by weight, 20-30 parts of cefprozil, 40-50 parts of probenecid, 2-5 parts of a binder, 10-20 parts of a diluent or a filler, 5-10 parts of a disintegrant, 1.0-3.0 parts of a lubricant, and 0.5-1.0 parts of a glidant; the film coating layer is a coating material, which accounts for 3-5% of the weight of the tablet core.
[0017] The active ingredients of the tablet are cefprozil and probenecid used in combination, preferably 27.8 parts of cefprozil and 41.7 parts of probenecid.
[0018] The adhesive is copolyvidone and a povidone series, that is, it contains at least one of K30 or K90, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and preferably the copolyvidone is 5 parts.
[0019] The tablet is a coated tablet, and the coating material is preferably 4 parts of Opadry.
[0020] The diluent or filler includes at least one of microcrystalline cellulose, lactose and compressible starch.
[0021] The adhesive comprises: copolyvidone; the disintegrant comprises: at least one of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, and low-substituted hydroxypropyl cellulose.
[0022] The lubricant comprises at least one of magnesium stearate, sodium stearyl fumarate and sodium lauryl sulfate.
[0023] The glidant comprises at least one of silicon dioxide, talcum powder and micro-powder silica gel.
[0024] A method for preparing a compound tablet composed of cefprozil and probenecid, characterized in that dry granulation is adopted, and the specific process is as follows:
[0025] (1) Pretreatment: First, pass probenecid through a 30-45 mesh sieve, then cross-sieve it with cefprozil, and all other added excipients are sieved for later use;
[0026] (2) Premixing: Mix the above auxiliary materials to obtain mixed powder.
[0027] (3) Dry granulation: The mixed powder is subjected to cold processing dry granulation, and the process parameters are: feeding speed 25-35 rpm, roller pressure 30-50 bar, granulation screen 18-20 mesh, condensed water temperature less than 40 °C.
[0028] (4) Total mixing: Add the external lubricant into the dry granulation material and mix.
[0029] (5) Tableting: The total mixed material is tableted.
[0030] (6) Coating: coating the plain tablets and packaging them to obtain the cefprozil / probenecid tablets of the present invention.
[0031] In the step 1, other raw and auxiliary materials are passed through a 40-mesh sieve; the premixing and total mixing time are both 10 minutes, and the production light intensity is dark-proof or yellow light conditions.
[0032] Furthermore, the dry granulation process parameters have a direct impact on the fluidity of the material after granulation. The process parameters are not fully optimized, the material granulation effect is extremely poor, the fine powder increases, and the fluidity is extremely poor. The loading amount in the tableting process has a great fluctuation, which directly affects the content uniformity of the product and causes unqualified quality problems. The dry granulation feeding speed of the present invention is 20-40rpm, preferably 25-30rpm; the roller pressure is 20-90bar, preferably 30-50bar; the granulation screen is 16-20 mesh, preferably 18-20 mesh.
[0033] Preferably, the preparation method of the cefprozil-probenecid tablets of the present invention comprises the following steps:
[0034] (1) Pretreatment: Pass probenecid through a 30-mesh sieve, and pass the remaining excipients and API through a sieve for later use.
[0035] (2) Premixing: Put the above materials into a mixer and mix them for 10 minutes until they are uniform.
[0036] (3) Dry granulation: The above materials are put into a dry granulator for granulation. The parameters are as follows: feed speed 25-30 rpm, roller pressure 30-50 bar, granulation screen 18 mesh, and condensed water temperature less than 40°C.
[0037] (4) Total mixing: Add the external lubricant to (3) and put them into a mixer together. Mix for 10 minutes and measure the active ingredient content.
[0038] (5) Tableting: The total mixed material is tableted, and the tablet hardness is 40 to 90N.
[0039] (6) Coating and packaging: The plain tablets are coated and packaged using moisture-proof and light-proof materials.
[0040] The coating solution used in the present invention is composed of a film coating premix-Opadry 2 prepared solution.
[0041] The formula of the present invention is obtained through process screening and prescription screening. During the screening process, pH 6.8 phosphate medium is used to detect probenecid. The screening process is as follows:
[0042] Process screening:
[0043] The initial process of the present invention performs preliminary screening based on the fluidity of the raw material itself, and dry granulation and wet granulation are preferred.
[0044] Wet granulation:
[0045] According to the following prescription, cefprozil and probenecid tablets were prepared with batch number 2401300101.
[0046]
[0047] The preparation steps are as follows:
[0048] First, cefprozil and probenecid are cross-sieved, and then other auxiliary materials are added and mixed, followed by wet granulation, and then dry granulation is performed after drying, and the external prescription amount of magnesium stearate is added thereto for total mixing and tableting.
[0049] Dry granulation:
[0050] According to the following prescription, cefprozil and probenecid tablets were prepared with batch number 24020301.
[0051]
[0052] The preparation steps are as follows:
[0053] First, cefprozil and probenecid are cross-sieved, and then other auxiliary materials are added, mixed, and dry granulated, and the converted external prescription amount of magnesium stearate is added thereto, mixed, and tableted.
[0054] The samples were tested for influencing factors and stability according to the Appendix of Part II of the 2020 edition of the Chinese Pharmacopoeia, and relevant substances were detected.
[0055]
[0056]
[0057] The results show that the overall summary of the preparation method of the present invention is that the total impurities of the wet granulation process batch are slightly greater than those of the dry granulation batch, and the dry granulation is preferred for the tablets of the present invention.
[0058] Prescription Screening:
[0059] 1. Dosage of solubilizer
[0060] In the prescription of the rapid-release tablet of the present invention, cefprozil is a BSC3 class, a high solubility, low permeability drug; probenecid is a BDDCS2 class, a low solubility, high metabolism drug. The proportion of probenecid in the tablet of the present invention is slightly high. In order to increase its solubility, a solubilizing agent component, such as sodium dodecyl sulfate (SDS), is designed to be added to the prescription. The effect of adding 2.5%, 2.0%, 1.5% and 0.0% SDS on the dissolution of the tablet is investigated in the prescription. The results are shown in the table.
[0061]
[0062] The experimental results show that adding SDS to the formula does not significantly affect the fluidity of the powder, and the solubility of the tablets does not change significantly, so it is confirmed that the solubilizer SDS is not added to the formula.
[0063] 2. Selection of adhesive
[0064] In the prescription of the instant release tablet of the present invention, the density of probenecid is relatively small, the raw material is loose, it is not easy to form thin slices after dry tableting, and the fine powder rate is also increased, so an adhesive is added to the prescription, and the adhesive includes hydroxypropyl cellulose, copolyvidone, etc. The novel auxiliary material copolyvidone is preferentially selected for research in this prescription, and copolyvidone is prepared by spray drying and has good fluidity. The effects of the prescriptions with 5% copolyvidone added and without copolyvidone added on the quality of powder and tablets are investigated in the prescription, and the results are shown in the table.
[0065]
[0066] The experimental results show that the addition of copolyvidone to the prescription reduces the powder fine powder rate and has no significant effect on the dissolution and hardness of the tablets. Therefore, it was determined that copolyvidone should be added to the prescription.
[0067] 3. Dosage of disintegrant and glidant
[0068] In the formulation of the instant release tablet of the present invention, sodium carboxymethyl starch (CMS-Na) is selected as a disintegrant, and the effects of adding 4%, 5%, 6%, and 7% of CMS-Na and adding 0.5% of a glidant on the dissolution of the tablet are investigated. The results are shown in the table.
[0069]
[0070] The experimental results show that there is no significant difference in dissolution when different amounts of CMS-Na are added to the prescription, and all meet the quality standards. The amount of disintegrant is 4.0% to 7.0%. Because this product is dry granulated, using too little or too much disintegrant may affect the dispersibility of the disintegrant, so the disintegrant selected is 7.0% sodium carboxymethyl starch.
[0071] Since probenecid has poor fluidity and has the phenomenon of agglomeration and wall adhesion, adding a flow aid can reduce the adverse risks after the prescription is enlarged. The experimental results show that adding a flow aid to the prescription can effectively reduce the wall adhesion phenomenon.
[0072] According to the above prescription screening, it can be concluded that the binder of the tablet of the present invention uses copovidone, the disintegrant is preferably sodium carboxymethyl starch and the usage accounts for 7%, and the usage of the glidant accounts for 0.5%.
[0073] Compared with the prior art, the present invention has the following positive effects:
[0074] (1) The tablet of the present invention fills the gap in the domestic β-lactam antibiotics (cephalosporin antibiotics) and probenecid tablet fields.
[0075] (2) The improved compound preparation of probenecid and cefuroxime can restore the efficacy of cefuroxime alone and significantly prolong the half-life of cefuroxime.
[0076] (3) The present invention overcomes the great difference in fluidity between the two raw materials of cefprozil and probenecid. When screening the preparation process, wet granulation and dry granulation are selected for comparison. Since cefprozil belongs to the β-lactam antibiotics and is prone to hydrolysis, cefprozil is slightly soluble in water, and the growth trend of related substances during the stability period is slightly higher than that of dry granulation, the preferred process is dry granulation. In order to reduce the influence of moisture on the tablets of the present invention, a coating process is performed.
[0077] (4) After dry granulation, the addition of the adhesive copolyvidone can effectively reduce the fine powder rate of the material, increase the adhesion between the materials, and also improve the compressibility and plasticity of the material, thereby promoting the formability of the tablet.
[0078] (5) In the preparation method of the present invention, cefprozil and probenecid are first cross-sieved, and then other auxiliary materials are added and mixed evenly, and then dry granulation is performed. Then, a lubricant is mixed with the above powders, tablets are pressed, and coating is performed. The tablets prepared by this method can reach the final dissolution amount, and the degradation of the β-lactam ring is less. BRIEF DESCRIPTION OF THE DRAWINGS
[0079] Figure 1 This is the diffraction pattern of cefprozil crystals.
[0080] Figure 2 The dissolution profile of the preparation of Example 2 in aqueous media under various conditions is shown in FIG.
[0081] Figure 3 The dissolution profiles of the formulation of Example 2 in a pH 6.8 medium under various conditions are shown. DETAILED DESCRIPTION
[0082] The present invention will be further described below in conjunction with the accompanying drawings and embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. The following embodiments are only used to illustrate the present invention, but are not intended to limit the scope of the present invention.
[0083] The experimental methods in the following examples, unless otherwise specified, are all conventional experimental methods in the art. The experimental materials used in the following examples, unless otherwise specified, are all conventional pharmaceutical grade excipients.
[0084] Example 1
[0085] According to the following prescription, cefprozil-propenecid tablets were prepared.
[0086]
[0087] The preparation steps are as follows:
[0088] First, cefprozil and probenecid are cross-sieved, and then other excipients are added for mixing and dry granulation is performed. The lubricant is added in the converted additional prescription amount for total mixing and tableting, and Opadry 2 solution is used for coating.
[0089] The samples are tested for influencing factors and stability in accordance with the Appendix of Part II of the 2020 edition of the Chinese Pharmacopoeia (specific details are determined based on the actual sampling time) to detect relevant substances.
[0090]
[0091] The results show that the addition of the adhesive copolyvidone has no significant difference in the changes of related substances. After adding the new auxiliary material copolyvidone, the sticking phenomenon of the tablets of the present invention is reduced.
[0092] Example 2
[0093] According to the following prescription, cefprozil-propenecid tablets were prepared.
[0094]
[0095] First, cefprozil and probenecid are cross-sieved, and then other excipients are added and mixed, followed by dry granulation. The lubricant is converted into the prescribed amount and added thereto for total mixing and tableting, and Opadry 2 solution is used for coating.
[0096] Comparison of stability data
[0097] A sample of cefprozil and probenecid tablets prepared in Example 2 of the present invention was taken, and the influencing factors and stability tests were carried out according to the Appendix of Part II of the 2020 edition of the Chinese Pharmacopoeia.
[0098] The main test items are properties, moisture, content and related substances. The test methods for related substances are as follows:
[0099] [Inspection] The relevant substances are determined according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512).
[0100] Test solution Take 4 tablets of this product, place them in a 200ml volumetric flask, add 60ml of mobile phase A (0.23% ammonium dihydrogen phosphate solution) and ultrasonically disintegrate, then add appropriate amount of methanol and ultrasonically disintegrate for 10min. After taking out, dilute to the scale with methanol, shake well, filter, take the filtrate and dilute it with diluent [0.23% ammonium dihydrogen phosphate solution-methanol (30:70)] to make a solution containing about 0.75mg of cefprozil and 1.125mg of probenecid per 1ml, shake well, and use it as the test solution.
[0101] Reference solution: Take appropriate amount of cefprozil and probenecid reference substances, weigh accurately, and quantitatively dilute with diluent to prepare a solution containing approximately 0.1 mg of cefprozil and 0.15 mg of probenecid per 1 ml, as the reference solution.
[0102] The chromatographic conditions are: octadecylsilane bonded silica gel as the filler (YMC Triart C18 250 mm × 4.6 mm, 5 μm or equivalent chromatographic column is recommended), 0.23% diammonium phosphate solution as mobile phase A, methanol as mobile phase B, and gradient elution according to the table below; flow rate is 1.0 ml per minute; column temperature is 25°C; wavelength is 225 nm; sample plate temperature is 5°C; injection volume is 10 μl.
[0103]
[0104] Determination method: Accurately measure the test solution and reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram.
[0105] If there are impurity peaks in the chromatogram of the limit test solution, calculate and report the content of each impurity and the total impurity content according to the main component external standard method using the probenecid peak area in the reference solution, and the reporting limit is (0.05%).
[0106] (1) Lighting test
[0107] The samples were placed naked and packaged under an illumination of 4500±500lx for 12 days (actually 11 days) to test properties, moisture, content, solubility and related substances. The results were compared with those of day 0 to examine the changes in various indicators. The results are shown in the table below.
[0108]
[0109] Note: When the analysis personnel confirmed the content of this product, the coating layer affected the sampling and weighing, resulting in slight differences in the content.
[0110] From the table above, we can see that after 11 days of strong light exposure, the properties, moisture and content of the naked and packaged samples have no significant changes compared with the test results on day 0. The related substances under the naked condition have increased, but all indicators still meet the requirements. From the above results, we can see that light has a slight effect on this product, and this product should be stored away from light.
[0111] (2) High temperature test
[0112] The samples were placed naked and packaged at a high temperature of 60℃±2℃ for 30 days, and the properties, moisture, content, solubility and related substances were tested at the same time. The results were compared with those on day 0 to examine the changes in various indicators. The results are shown in the table below.
[0113]
[0114] From the table above, we can see that after the naked and packaged samples were placed under high temperature conditions for 30 days, compared with the test results on day 0, the properties, moisture and content of the samples did not change significantly. High temperature has strong thermal penetration, and the related substances of the naked and packaged samples increased, but all indicators still meet the requirements. From the above results, we can see that high temperature has a slight effect on this product, and this product should be stored at room temperature.
[0115] (3) High humidity test
[0116] The samples were placed naked and packaged at high humidity of 75% ± 5% for 30 days, and the properties, moisture, content, solubility and related substances were tested. The results were compared with those on day 0 to examine the changes in various indicators. The results are shown in the table below.
[0117]
[0118] From the table above, we can see that after the naked and packaged samples were placed under high humidity conditions for 30 days, compared with the test results on day 0, the properties, moisture and content of the samples did not change significantly. The high humidity penetration was strong, and the related substances of the naked and packaged samples increased, but all indicators still met the requirements. From the above results, we can see that high humidity has a slight effect on this product, and this product should choose packaging materials with good moisture-proof properties.
[0119] (4)Acceleration conditions
[0120] The packaged samples were placed in a stability sampling box at 40℃±2℃ and 75%±5%RH for 1 month and 2 months, and the properties, moisture, content, solubility and related substances were tested at the same time. The results were compared with those on day 0 to examine the changes in various indicators. The results are shown in the table below.
[0121]
[0122] From the table above, we can see that the properties, moisture content and
[0123] The trend of change is slow, and the related substances of this product have slightly increased. After analysis, the main impurity change is cefprozil, which itself has slightly poor stability under high temperature and high humidity conditions, while probenecid has better stability. After the combination of the two, the compound preparation has good stability under accelerated conditions and also meets the quality standards of this product.
[0124] Under strong light, high temperature, high humidity and accelerated conditions, the cefprozil in this product can quickly dissolve in water to reach the final dissolution amount as shown in the attached Figure 2 As shown in the attached figure, probenecid in this product can also quickly dissolve in a pH 6.8 medium under strong light, high temperature, high humidity and accelerated conditions to reach the final dissolution amount. Figure 3As shown above, in summary, the compound preparation of this product meets the quality standards of this product under various influencing conditions and stability conditions, which shows that this product has high stability.
[0125] Example 3
[0126] A compound tablet composed of cefprozil and probenecid is prepared. First, 20 parts of cefprozil and 40 parts of probenecid are cross-sieved through a 30-mesh screen by weight, and then other auxiliary materials, namely, 2 parts of copovidone, 10 parts of microcrystalline cellulose, 5 parts of cross-linked polyvinylpyrrolidone and 0.5 parts of silicon dioxide, are added and mixed in a mixer for 10 minutes. The materials are put into a dry granulator for granulation, and the parameters are as follows: a feeding speed of 25 rpm, a roller pressure of 30 bar, a granulation screen of 18 meshes, and a condensed water temperature of less than 40 DEG C. Then, 1.0 part of lubricant magnesium stearate is added and mixed for 10 minutes, the content of active ingredients is determined, and the total mixed material is tableted, and the tablet hardness is 40N. Finally, the plain tablet is coated, namely, the coating material is added to 3% of the weight of the tablet core, and the tablet is packaged, and a moisture-proof and light-proof material is selected for packaging.
[0127] Example 4
[0128] First, 27.8 parts of cefprozil and 41.7 parts of probenecid are cross-sieved through a 30-mesh sieve by weight, and then other auxiliary materials, such as 5.0 parts of a povidone series (containing K30 or K90), 15.5 parts of lactose, 7.0 parts of cross-linked carboxymethyl cellulose sodium, and 2.5 parts of talc, are added and mixed in a mixer for 10 minutes, and the above materials are put into a dry granulator for granulation, and the parameters are a feeding speed of 30 rpm, a roller pressure of 50 bar, a granulation sieve of 18 mesh, and a condensed water temperature of less than 40° C.; then 2.5 parts of a lubricant, sodium stearyl fumarate, are added and mixed for 10 minutes, the content of the active ingredient is determined, and the total mixed material is tableted, and the tablet hardness is 90N; finally, the plain tablets are coated, that is, the coating material is added to 5% of the weight of the tablet core, and packaged, and a moisture-proof and light-proof material is selected for packaging.
[0129] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with the profession can make some changes or modifications to the technical content disclosed above to obtain equivalent embodiments of equivalent changes without departing from the scope of the technical solution of the present invention. However, any modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the technical solution of the present invention.
Claims
1. A compound tablet composed of cefprozil and probenecid, characterized in that: Cefprozil and probenecid are the active ingredients.
2. The compound tablet of cefprozil and probenecid according to claim 1, characterized in that The cefprozil is a monohydrate compound.
3. The compound tablet composed of cefprozil and probenecid according to claim 1, characterized in that The pharmaceutical composition is a tablet, which comprises a tablet core and a film coating layer. The tablet comprises, by weight: 20-30 parts of cefprozil, 40-50 parts of probenecid, 2-5 parts of a binder, 10-20 parts of a diluent, 5-10 parts of a disintegrant, 1.0-3.0 parts of a lubricant, and 0.5-1.0 parts of a glidant; the film coating layer is a coating material, which accounts for 3-5% of the weight of the tablet core.
4. The compound tablet composed of cefprozil and probenecid according to claim 3, characterized in that The active ingredients of the tablet are cefprozil and probenecid used in combination, preferably 27.8 parts of cefprozil and 41.7 parts of probenecid.
5. The compound tablet composed of cefprozil and probenecid according to claim 3, characterized in that The adhesive is copolyvidone and a povidone series, that is, it contains at least one of K30 or K90, hydroxypropyl cellulose, and hydroxypropyl methylcellulose, and preferably the copolyvidone is 5 parts.
6. The compound tablet composed of cefprozil and probenecid according to claim 3, characterized in that The tablet is a coated tablet, and the coating material is preferably 4 parts of Opadry.
7. The compound tablet composed of cefprozil and probenecid according to claim 3, characterized in that The tablet composition comprises 15.5 parts of diluent or filler, 7.0 parts of disintegrant, 2.5 parts of lubricant and 0.5 parts of glidant; The diluent or filler includes: at least one of microcrystalline cellulose, lactose, and compressible starch; The disintegrant comprises: at least one of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, and low-substituted hydroxypropyl cellulose; The lubricant comprises: at least one of magnesium stearate, sodium stearyl fumarate, and sodium lauryl sulfate; The glidant comprises at least one of silicon dioxide, talcum powder and micro-powder silica gel.
8. The compound tablet composed of cefprozil and probenecid according to claim 3, characterized in that The preparation method of the tablet comprises the following steps: (1) Pretreatment: First, sieve probenecid through a 30-mesh sieve, then cross-sieve it with cefprozil, and sieve the remaining added excipients for later use; (2) Premixing: Put the above materials into a mixer and mix them for 10 minutes until they are evenly mixed; (3) Dry granulation: The above materials are put into a dry granulator for granulation, and the parameters are as follows: a feed speed of 25 to 30 rpm, a roller pressure of 30 to 50 bar, a granulation screen of 18 mesh, and a condensed water temperature of less than 40°C; (4) Total mixing: Add the external lubricant to (3) and put them into a mixer together for mixing for 10 minutes, and measure the active ingredient content; (5) Tableting: The total mixed material is tableted, and the tablet hardness is 40 to 90N; (6) Coating and packaging: The plain tablets are coated and packaged using moisture-proof and light-proof materials.
9. The compound tablet composed of cefprozil and probenecid according to claim 8, characterized in that In the step 1, other raw and auxiliary materials are passed through a 40-mesh sieve; the premixing and total mixing time are both 10 minutes, and the production light intensity is dark-proof or yellow light conditions.
